The Vaccine and Immunotherapy Center in partnership with Voltron Therapeutics, Inc. has selected three initial cancer targets and pre-clinical protocols for its VaxCelerate self-assembling vaccine (SAV) platform, in the immuno-oncology (IO) setting and are aiming to file an IND for at least one cancer indication in mid-2022.
Please read the press release below for more detail on this exciting progress.
